BLINK2 study reveals when to discontinue soft multifocal contact lens wear in pediatric patients

News
Video

Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).

Jeffrey Walline, OD, PhD, FAAO, recently spoke on the primary endpoints of the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI). The study found that no evidence of a loss of treatment effect after discontinuing multifocal contact lenses in older teenagers. At baseline for BLINK2, mean (SD) axial length and spherical equivalent refractive error were 25.2 (0.9) mm and −3.40 (1.40) D, respectively. After participants switched from multifocal to single-vision contact lenses, axial elongation increased by 0.03 mm per year (95% CI, 0.01 to 0.05) regardless of their original BLINK treatment assignment (P = .81).

Video transcript

Editor's note: This transcript has been lightly edited for clarity.

Jeffrey Walline, OD, PhD, FAAO:

I did a recent presentation on end points for studies of refractive error and myopia control. And I think the takeaways from that are that axial elongation has become a very important part of myopia control. As a matter of fact, I think we would consider it the primary outcome today. The reason that it's now the primary outcome is we have a much better understanding as a profession, and we're much better able to educate our patients about what eye growth means. So what is slow eye growth? What is fast eye growth? What are the ramifications of the eye growing too much? And it's those kinds of things that I really think help make the evolution of optometric studies and sort of change the primary focus from the progression of myopia to the growth of the eye.

So the Bifocal Lenses in Nearsighted Kids, or BLINK study, found that soft multifocal contact lenses, if you use the high reading add or the 250-add slow the progression of myopia in children. But what we've recently found is that if you discontinue those contact lenses, the rate of myopia progression will actually increase, but it only increases to a rate that is equal to those people who receive no treatment. So you don't lose the treatment effect by discontinuing contact lens wear after the age of 16, 17, 18, years of age. So our recommendation that we've always had sort of continues to stand, and that is, if you feel like you need to discontinue soft multifocal contact lens wear, wait until after the age of expected progression, after age 15 or 16, and then when you discontinue, yes, eye growth will increase, but it won't increase enough to make you lose the treatment effect that you gained by wearing those for the previous years.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.